Major Depressive Disorder (MDD) - Drug Pipeline Analysis and Market Forecasts to 2015

Report Summary

GlobalData, the industry analysis specialist, has released its new report, “Major Depressive Disorder - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global Major depressive Disorder (MDD) therapeutics market. The report identifies the key trends shaping and driving the global MDD therapeutics market. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. Most importantly, the report provides valuable insights into the pipeline products within the global MDD sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData estimates the global MDD therapeutics market to be valued at $11.02bn in 2009. The market is estimated to decline by 3% to $9.0bn in 2017, which is attributed to patent expiry of Lexapro and Cymbalta in 2012 and 2013.  However, the MDD market is anticipated to stabilize with the expected approval of Vilazodone and TC-5214 and the increasing public awareness.

Scope

The scope of the report includes:

• Annualized global Hepatitis B therapeutics market revenue data from 2001 to 2009, forecast for eight years to 2017.
• Geographies covered in this report include the United States (US), the United Kingdom (UK), Italy, Spain, Germany, France and Japan.
• Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include selective serotonin reuptake inhibitor, serotonin and nenorepinephrine reuptake inhibitor, cortiocotropin releasing factor antagonist and AMPA receptor modulator.
• Analysis of the current and future market competition in the global MDD therapeutics market. The key future market players covered are GlaxoSmithkline, AstraZeneca, Forest Laboratories, Merck & Co., Eli Lilly, Weyth (Pfizer) and Lundbeck.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
• Key topics covered include a strategic competitor assessment, a market characterization, the unmet needs and the implications for the MDD therapeutics market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to:

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipelines.
• Develop business strategies by understanding the trends shaping and driving the global MDD therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to affect the global MDD therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investments and strategic partnerships.
• What’s the next big thing in the global Hepatitis B therapeutics market landscape? Identify, understand and capitalize.

1 Table of contents 3

1.1 List of Tables 5
1.2 List of Figures 5

2 Major Depressive Disorder Market: Introduction 6
2.1 GlobalData Pipeline Report Guidance 6

3 Major Depressive Disorder Market: Market Characterization 7
3.1 Overview 7
3.2 Depressive Disorder Market Size 7
3.3 Depression Market Forecast and CAGR 8
3.4 Drivers and Barriers for the Major Depressive Disorder Market 10
3.4.1 Drivers for the Major Depressive Disorder Market 10
3.4.2 Barriers for the Major Depressive Disorder Market 10
3.5 Opportunity and Unmet Need 11
3.6 Key Takeaway 12

4 Major Depressive Disorder Market: Competitive Assessment 13
4.1 Overview 13
4.2 Strategic Competitor Assessment 13
4.3 Product Profile for the Major Marketed Products in the Major Depressive Disorder Market 14
4.3.1 Lexapro/Cipralex (Escitalopram oxalate) 14
4.3.2 Cymbalta (Duloxetine Hydrochloride) 15
4.3.3 Abilify (Aripiprazole) 16
4.3.4 Pristiq (Desvenlafaxine succinate) 17
4.3.5 Symbyax (Olanzapine and fluoxetine Hcl) 18
4.4 Key Takeaway 20

5 Major Depressive Disorder Market: Pipeline Assessment 21
5.1 Overview 21
5.2 Strategic Pipeline Assessment 21
5.2.1 Technology Trends Analytic Framework 21
5.3 Major Depressive Disorder Therapeutics – Promising Drugs under Clinical Development 23
5.4 Molecule Profile for Promising Drugs under Clinical Development 24
5.4.1 Vilazodone 24
5.4.2 TC 5214 25
5.4.3 LU AA21004 25
5.5 Major Depressive Disorder Therapeutics Market – Clinical Pipeline by Mechanism of Action 26
5.6 Major Depressive Disorder – Pipeline by Clinical Phases of Development 27
5.6.1 Major Depressive Disorder Therapeutics – Phase III Clinical Pipeline 28
5.6.2 Major Depressive Disorder Therapeutics – Phase II Clinical Pipeline 29
5.6.3 Major Depressive Disorder Therapeutics – Phase I Clinical Pipeline 31
5.7 Key Takeaway 31

6 Major Depressive Disorder Market: Implications for Future Market Competition 32

7 Major Depressive Disorder Market: Future Players in the MDD Market 33
7.1 Introduction 33
7.2 GlaxoSmithKline plc. 33
7.2.1 Overview 33
7.2.2 CNS Portfolio 34
7.2.3 Major Depressive Disorder Product Portfolio 35
7.3 AstraZeneca 35
7.3.1 Overview 35
7.3.2 CNS Portfolio 36
7.3.3 Major Depressive Disorder Product Portfolio 37
7.3.4 AZD2327 37
7.4 H.Lundbeck A/S 38
7.4.1 Overview 38
7.4.2 CNS Portfolio 38
7.4.3 Major Depressive Disorder Product Portfolio 39
7.5 Pfizer Inc 40
7.5.1 Overview 40
7.5.2 CNS Portfolio 40
7.5.3 Major Depressive Disorder Product Portfolio 42
7.6 Eli Lilly and Company 42
7.6.1 Overview 42
7.6.2 CNS Portfolio 42
7.6.3 Major Depressive Disorder Product Portfolio 43

8 Major Depressive Disorder Market: Appendix 44
8.1 Market Definitions 44
8.2 Scope of Pipeline Research 44
8.3 Abbreviations 44
8.4 Research Methodology 45
8.4.1 Coverage 45
8.4.2 Secondary Research 46
8.4.3 Forecasting 46
8.4.4 Primary Research 49
8.4.5 Expert Panel validation 49
8.5 Contact Us 49
8.6 Disclaimer 50
8.7 Sources 51

1.1 List of Tables

Table 1: MDD Therapeutics, Global, Market Revenue ($bn), 2001–2009 8
Table 2: MDD Therapeutics, Global, Market Forecast ($bn), 2009-2017 9
Table 3: Major Marketed Products Comparison in the Major Depressive Disorder Market, 2010 19
Table 4: Major Depressive Disorder Therapeutics – Most Promising Drugs Under Clinical Development, 2010 23
Table 5: Major Depressive Disorder Therapeutics – Phase III Clinical Pipeline, 2009 28
Table 6: Major Depressive Disorder Therapeutics – Phase II Clinical Pipeline, 2009 29
Table 7: Major Depressive Disorder Therapeutics – Phase I Clinical Pipeline, 2009 31
Table 8: GlaxoSmithKline plc – CNS Marketed Products, 2009 34
Table 9: GlaxoSmithKline plc – CNS Pipeline Products, 2009 34
Table 10: AstraZeneca – CNS Marketed Products, 2009 36
Table 11: AstraZeneca – CNS Pipeline Products, 2009 36
Table 12: H.Lundbeck A/S– CNS Marketed Products, 2009 38
Table 13: H. Lundbeck A/S – CNS Pipeline Products, 2009 38
Table 14: Pfizer Inc – CNS Marketed Products, 2009 40
Table 15: Pfizer Inc– CNS Pipeline Products, 2009 41
Table 16: Eli Lilly and Company– CNS Marketed Products, 2009 42
Table 17: Eli Lilly and Company – CNS Pipeline Products, 2009 43

1.2 List of Figures

Figure 1: MDD Therapeutics, Global Revenue ($m), 2001–2009 8
Figure 2: MDD Therapeutics, Global, Market Forecast ($m), 2009–2017 9
Figure 3: Opportunity and Unmet Need in the MDD Therapeutics Market, 2010 12
Figure 4: Opportunity and Unmet Need in the MDD Therapeutics Market, 2010 13
Figure 5: Technology Trends Analytic Framework of the MDD Pipeline, 2010 21
Figure 6: MDD Therapeutics – Clinical Pipeline by Mechanism of Action, 2010 26
Figure 7: MDD Therapeutics - Pipeline by Phase of Clinical Development, 2010 27
Figure 8: Implications for Future Market Competition in the MDD Therapeutics Market, 2010 32
Figure 9: MDD Therapeutics Market – Clinical Pipeline by Company, Number of Molecules, 2010 33
Figure 10: GlobalData Market Forecasting Model 48